Loading stock data…
$37.00-0.92 (-2.43%)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Nektar Therapeutics in the Healthcare sector is trading at $37.00 with a market capitalization of $2.3B. Wall Street consensus targets $133.08 (12 analysts), implying a +259.7% move over the next 12 months. The stock is currently near its 52-week low of $33.40, remaining 43.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.13M↓ | $10.86M↓ | $21.81M↑ | $11.79M↑ | $11.18M |
| Gross Profit | — | — | $21.81M↑ | $11.79M↑ | $11.18M |
| Operating Income | -$41.76M↓ | -$38.26M↓ | -$19.09M↑ | -$31.53M↑ | -$35.78M |
| Net Income | -$40.62M↑ | -$44.90M↓ | -$36.08M↓ | -$35.52M↑ | -$41.59M |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune s...